Valeant Pharmaceuticals International Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “underperform” rating reiterated by analysts at Wells Fargo & Co. in a research note issued to investors on Friday. They currently have a $11.50 price target on the specialty pharmaceutical company’s stock, down from their previous price target of $19.50. Wells Fargo & Co.’s price objective would suggest a potential downside of 37.33% from the company’s current price.

Several other equities analysts have also issued reports on VRX. Scotiabank restated a “sector perform” rating and set a $17.00 price target (down from $32.00) on shares of Valeant Pharmaceuticals International in a research report on Thursday, November 10th. Mizuho restated a “neutral” rating and set a $25.00 price target on shares of Valeant Pharmaceuticals International in a research report on Tuesday, November 1st. Morgan Stanley reduced their price target on Valeant Pharmaceuticals International from $42.00 to $25.00 and set an “overweight” rating on the stock in a research report on Thursday, November 10th. Piper Jaffray Cos. set a $22.00 price target on Valeant Pharmaceuticals International and gave the stock a “sell” rating in a research report on Friday, August 19th. Finally, Canaccord Genuity restated a “hold” rating and set a $28.00 price target on shares of Valeant Pharmaceuticals International in a research report on Wednesday, August 10th. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $39.63.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Shares of Valeant Pharmaceuticals International (NYSE:VRX) opened at 18.35 on Friday. The firm’s market cap is $6.38 billion. The firm has a 50-day moving average of $20.71 and a 200-day moving average of $24.35. Valeant Pharmaceuticals International has a 12-month low of $13.77 and a 12-month high of $119.87.

Valeant Pharmaceuticals International (NYSE:VRX) last announced its quarterly earnings data on Tuesday, November 8th. The specialty pharmaceutical company reported $1.55 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.78 by $0.23. The firm had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.49 billion. Valeant Pharmaceuticals International had a negative net margin of 22.17% and a positive return on equity of 43.81%. The business’s quarterly revenue was down 11.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.74 earnings per share. On average, equities analysts forecast that Valeant Pharmaceuticals International will post $5.43 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its position in Valeant Pharmaceuticals International by 6.7% in the second quarter. Tower Research Capital LLC TRC now owns 6,405 shares of the specialty pharmaceutical company’s stock worth $129,000 after buying an additional 402 shares during the period. Kistler Tiffany Companies LLC raised its position in Valeant Pharmaceuticals International by 95.5% in the third quarter. Kistler Tiffany Companies LLC now owns 5,567 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 2,719 shares during the period. US Bancorp DE raised its position in Valeant Pharmaceuticals International by 141.0% in the third quarter. US Bancorp DE now owns 5,745 shares of the specialty pharmaceutical company’s stock worth $141,000 after buying an additional 3,361 shares during the period. D.A. Davidson & CO. raised its position in Valeant Pharmaceuticals International by 22.6% in the third quarter. D.A. Davidson & CO. now owns 5,980 shares of the specialty pharmaceutical company’s stock worth $146,000 after buying an additional 1,103 shares during the period. Finally, Cacti Asset Management LLC raised its position in Valeant Pharmaceuticals International by 68.0% in the second quarter. Cacti Asset Management LLC now owns 8,400 shares of the specialty pharmaceutical company’s stock worth $169,000 after buying an additional 3,400 shares during the period. 67.13% of the stock is owned by hedge funds and other institutional investors.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.